The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial

Journal:

Nature Medicine

Published:

2025-07-16

DOI:

10.1038/s41591-025-03781-w

Affiliations:

30

Authors:

32

Go to article

Institutions	Authors	Share
Hengrui, China	3.000000	0.09
State Key Laboratory of Oncology in South China, SYSUCC, China	2.500000	0.08
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), China	2.500000	0.08
Shandong Cancer Hospital, China	2.000000	0.06
Tianjin Medical University Cancer Institute and Hospital, TMU, China	2.000000	0.06
The First Affiliated Hospital, SYSU, China	2.000000	0.06
Zhujiang Hospital of Southern Medical University, China	2.000000	0.06
Peking University First Hospital, PKUHSC, China	2.000000	0.06
Xiangya Hospital, CSU, China	2.000000	0.06
Henan Cancer Hospital, ZZU, China	1.000000	0.03
Hubei Cancer Hospital (HBCH), China	1.000000	0.03
Shanxi Cancer Hospital, China	1.000000	0.03
Harbin Medical University Cancer Hospital, China	1.000000	0.03
First Affiliated Hospital, ZZU, China	1.000000	0.03
Renji Hospital, SJTU, China	1.000000	0.03
Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital (SAMSPH), China	1.000000	0.03
Qilu Hospital of Shandong University, China	1.000000	0.03
The First Affiliated Hospital of Xi'an Jiaotong University, XJTU, China	1.000000	0.03
The First Affiliated Hospital of Henan University of Science and Technology, China	1.000000	0.03
Tumor Hospital of Guangxi Medical University, China	1.000000	0.03
The First Affiliated Hospital of Nanchang University, China	1.000000	0.03

Interested in Oncology and Carcinogenesis?